Description: Cure the incurable
biopharmaceutical company (32) cancer drug discovery and development (1)
SpeedyAb™ technology platform provides high-throughput features of antibody screening for obtaining the therapeutic leads with high affinity and broad diversity.
ImmunoBuster I+II™ technology platform develops one-shot vaccines with strong immunogenicity for prophylactic and therapeutic treatment without additional boost. An immunological module for eliciting quick yet rebust immunity and is comparable with commercially available vaccine.
TsKill™ technology platform enables low frequency of tumor-specific T cells to effectively destroy tumors by enhancing the functionality of effector cells and tumor recognition.